导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.25% | 2260/4773 |
| 近一周 | -1.47% | 461/5462 |
| 近一月 | -1.15% | 869/5421 |
| 近一季 | -3.47% | 1414/5209 |
| 近半年 | -4.12% | 2434/4920 |
| 近一年 | 2.44% | 2115/4366 |
| 近两年 | 45.22% | 1632/2954 |
| 近三年 | 27.11% | 1178/2253 |
| 成立以来 | 102.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.05% 2084/4961 |
4.12% 2920/5312 |
- - |
- - |
| 2025 | 19.80% 2179/4813 |
-0.06% 2046/3635 |
4.94% 678/4076 |
11.53% 3153/4524 |
2.43% 954/4813 |
| 2024 | 11.26% 1336/3463 |
1.51% 878/2808 |
-1.76% 1105/3014 |
11.42% 2520/3129 |
0.12% 1264/3463 |
| 2023 | 0.69% 398/2656 |
6.77% 646/2280 |
-0.58% 391/2385 |
-0.65% 431/2515 |
-4.52% 1072/2655 |
| 2022 | -12.14% 272/2207 |
-8.86% 300/1919 |
5.00% 952/2016 |
-9.33% 269/2113 |
1.26% 1325/2208 |
| 2021 | 5.24% 554/1822 |
-0.89% 404/1255 |
2.58% 995/1330 |
2.58% 435/1466 |
0.92% 1043/1822 |
| 2020 | 20.66% 711/1250 |
-6.86% 512/1028 |
9.93% 778/1067 |
9.34% 656/1164 |
7.78% 694/1184 |
| 2019 | 28.93% 513/1092 |
21.67% 595/754 |
-1.14% 297/804 |
1.24% 421/850 |
5.88% 668/918 |
| 2018 | -20.03% 186/834 |
- - |
- - |
- - |
-10.50% 200/691 |
| 2017 | 7.71% 315/714 |
- - |
- - |
- - |
- - |
| 2016 | -9.39% 259/605 |
- - |
- - |
- - |
- - |
| 2015 | 7.33% 175/575 |
- - |
- - |
- - |
- - |
| 2014 | 53.38% 62/237 |
- - |
- - |
- - |
- - |
| 2013 | -3.69% 79/186 |
- - |
- - |
- - |
- - |
| 2012 | 5.58% 74/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国上证指数ETF联接A VS. 长安沪深300非周期A(740101) |